PIA
ALDX icon

Piedmont Investment Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Piedmont Investment Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-276
Closed -$2K – 1082
2018
Q2 		$2K Buy
+276
New +$2.2K ﹤0.01% 2531

Other funds holding ALDX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Piedmont Investment Advisors's ALDX Position: Q3 2018 in Review

Piedmont Investment Advisors sold out of Aldeyra Therapeutics (ALDX) in Q3 2018, closing a stake of 276 shares — an estimated $2K sold.

Piedmont Investment Advisors first reported a position in ALDX in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 89 funds tracked by Wall St. Rank hold ALDX as of Q3 2018.

  • Piedmont Investment Advisors reported no remaining Aldeyra Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piedmont Investment Advisors sold 276 Aldeyra Therapeutics shares in Q3 2018, an estimated $2K.
  • Piedmont Investment Advisors first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 1 quarter.
  • Piedmont Investment Advisors's Aldeyra Therapeutics position peaked at $2K in Q2 2018.
  • 89 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q3 2018.

Based on Piedmont Investment Advisors's 13F filing for Q3 2018, filed 8 Nov 2018.